35 results about "Pathologic" patented technology

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Systems and methods for the improved quantitative assessment of airway mucus plug pathology are provided herein which provide a quantitative suite of mucus imaging metrics that objectively quantifies features of mucus plug pathology in the lungs. Systems and methods for generating a subject-level mucus plug map that illustrates the position of one or more whole mucus plugs, or the absence of mucus plugs in an airway tree are discussed. Systems and methods for the determination of a subject-level mucus plug phenotype are provided herein.

The present disclosure relates to a method of treating, preventing or delaying an age-related condition or pathology in a mammal using extracellular vesicles (EVs) derived from a young mammal.

The invention relates to negative functional modulators of at least one variant of the non-erythrogenic erythropoietin (V-EPO) and pharmaceutical compositions or kits containing them. Such functional negative modulators of V-EPO may be a mono- or multi-specific antibody anti-EV3, anti-EV4, anti-EV1-4, anti-EV1-5, anti-EV1-1, or EV2-1, or anti-Epo receptor (EpoR) anti-EPHB4, anti-CSF2RB, an antisense oligonucleotide, DNA decoy, RNA decoy, a ribozyme, an antagomiR, a shRNA, LNA or siRNA.Several uses of these functional modulators are described, which have been advantageously employed as a medicament and for the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing organ or tissue transplantation.The invention also describes variants of EPO for use in the diagnosis and in the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing an organ or tissue transplantation and as a diagnostic agent.According to another aspect, a monoclonal antibody to at least one of the variants of the erythropoietin is described.According to yet another aspect, the use of at least one alternative splicing variant of non-erythrogenic EPO and the measurement thereof at tissue and / or systemic level is described, as well as the study of the methylation status of the promoters of the genes involved in the EPO signalling pathway (by way of example EPO, EPOR, EPHB4, CSF2RB), as diagnostic, prognostic and predictive markers of an oncological pathology, a proliferative pathology, neurodegenerative or inflammatory pathology.

Described herein are EphA4 receptor antagonists, pharmaceutical compositions containing EphA4 antagonists, and methods and uses of treating an EphA4-based disease, disorder or pathology in an individual using EphA4 receptor antagonists.

A benzene sulfonamide compound of formula I or one of its addition salts with pharmaceutically acceptable acids, for use in a method of treating a pathology related to an excessive effect of TNF and for use in a method of treating the human or animal body.

In some aspects, the described systems and methods provide for a method for training a deep learning model to assess liver pathology, including accessing annotated liver pathology images associated with a group of patients in one or more randomized controlled clinical trials of nonalcoholic steatohepatitis therapy, each of the annotated liver pathology images including at least one annotation describing one or more tissue characteristic categories for a portion of the image, and training the deep learning model based on the annotated liver pathology images to predict the tissue characteristic categories, selected from a group comprising steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis stage.

Described herein are various embodiments of techniques for determining reference values / ranges for diagnostic markers for patients during treatment and recovery during and / or after illness or injury. Some methods may include obtaining a patient's medical information (including any diagnosed medical conditions) and calculating, based on the medical condition and an elapsed time since onset or start of treatment, expected reference ranges for one or more diagnostic markers. These methods may also include outputting an indication of whether the measurements for the diagnostic marker or markers fall outside the reference range(s). In some embodiments, the reference values can be adjusted depending on additional pathologies indicated in the patient's medical information. Some such patient- and / or pathology-specific reference values / ranges can also be displayed to medical professionals to aid in patient care and / or leveraged in automated patient monitoring systems to alert doctors that a patient is not recovering according to the expected trajectory.

The present application discloses, as an embodiment of the invention, a compound, or a pharmaceutically acceptable salt thereof, that is useful as an agent for preventing or treating a disease caused by a decrease in autophagy function or a disease in which a pathological condition is suppressed or improved by the enhancement of autophagy function, and that is represented by formula (I) (in formula, the symbols are as described in the specification).

A computer-implemented system and method for predicting and diagnosing osteoporosis based on magnetic resonance imaging technology is disclosed. In particular, the method of the present invention is a reliable, reproducible and sensitive method for providing a reliable, reliable, reproducible and sensitive method for detecting, by simple and fast statistical processing, i.e. Only by statistically correlating recorded MRI of a subject with recorded MRI of a reference group, independent of other standard techniques such as, for example, clinical diagnosis of MOC, QCT, DXA or osteoporosis. Osteoporosis is predicted or diagnosed from the magnetic resonance image. In this aspect, any patient who experiences magnetic resonance imaging for reasons independent of osteoporosis can receive his / her diagnostic information about the medical state of osteoporosis, regardless of how, without additional studies or tests and without the use of ionizing radiation, regardless of the suspicion of the previous osteoporotic pathology. This is very valuable and ideal in that in this way, although the asymptomatic nature of osteoporosis, it is possible to early identify patients at risk of osteoporosis or in which pathology has progressed. In addition, the overall method of the invention is very convenient, so that neither the patient nor the national health system assumes additional expenses.

The present invention relates to compounds and compositions for use in a method of treating and / or preventing neurological or non-neurological channelopathies, i.e., pathologies which are caused specifically by defects in some of the calcium-activated potassium channels. Specific neurological channelopathies and / or synaptopathies targeted by the present invention include specific neuropsychiatric pathologies, such as particularly Fragile X Syndrome (FXS), Angelman syndrome, Williams-Beuren syndrome, autism, Autism spectrum disorders (ASDs), hyperacusis, Smith-Magenis syndrome, Prader-Willi syndrome, 7q11.23 duplication syndrome, and cri-du-chat syndrome, as well as other neuropathic disorders such as trembling, epilepsy and neuropathic pains associated and neurodegenerative diseases such as Parkinson's and Alzheimer diseases. Compounds, compositions and methods of the present invention are also particularly useful and efficient in alleviating neurological symptoms common to these neuropsychiatric pathologies.

The present disclosure generally relates to compositions and methods to increase resistance to age-related pathologies, improve physiological state or disorder related to cell ageing or metabolic fatigue in one or more cells; improve mobility and / or healthspan and / or lifespan of an adult animal in need. More specifically, the present disclosure relates to administering a formulation comprising an effective amount of nicotinamide (NAM) and Glycine, optionally an autophagy inducer.

Described herein are methods of assessing the risk of dementia in a subject using an odor-based test, or "smell test". These methods can be self-administered by the subject under the instruction of a computing device via a user interface. Methods of administering a smell test as described herein can optionally be combined with measuring and quantifying the level of at least one biomarker for dementia (e.g., CXCL10, CCL2, IL-6) in a biological sample collected from the subject. Also provided are methods to treat dementia (e.g., dementia associated with Alzheimer's disease, dementia associated with a subset of Alzheimer's disease patients with TDP-43 pathology).

Disclosed are 4-aminopyrrolo [2, I-f] [1, 2, 4] triazine compounds of Formula I for the treatment of various diseases and pathologies. More specifically, the present disclosure relates to the use of 4-aminopyrrolo [2, 1-f] [1, 2, 4] triazine compounds or analogs thereof in the treatment of conditions characterized by DYRK1A overexpression (e.g., cancer, Down's syndrome, Alzheimer's disease, diabetes, and osteoarthritis).

Compositions, methods, and kits are provided for diagnosing vitreoretinal diseases and age-related pathologies. In particular, aqueous humor biomarkers have been identified that correlate with biological aging and age-related pathologies and morbidity. The use of such biomarkers may allow earlier intervention in treatment of aging-related diseases. In addition, methods of using aqueous humor biomarkers for prognosis, diagnosis, and monitoring treatment of vitreoretinal diseases are also provided.

The present disclosure relates to a method for generating a trained classifier adapted to detect a targeted pathology in a body fluid sample, the method comprising: processing a set of body fluid samples each being associated with a presence indicator of the targeted pathology, to obtain processed samples each comprising a list of exRNAs comprising values representative of occurrence numbers of the exRNAs, detected in the body fluid sample; training machine learning models using the processed samples and a presence indicator of the targeted pathology associated with the processed samples; testing the trained machine learning models; generating a list of selected exRNA as a function of the scores attributed by the trained machine learning models; and training a classifier using the processed samples and the presence indicator of the targeted pathology, the trained classifier and the list of selected exRNA being used to detect the targeted pathology.

The application belongs to the technical field of biological medicine, and provides application of ILDR3 gene and / or protein in preparation of a drug for preventing and / or treating a Tau-related disease and a diagnostic product. The ILDR3 provided in the application is a key treatment target of the Tau-related disease, can simultaneously intervene in multiple core links of the Tau pathology, including promoting degradation of the Tau protein, inhibiting excessive phosphorylation thereof and blocking abnormal aggregation thereof. Experimental data show that the expression of ILDR3 is down-regulated in the Tau-related disease, knocking out ILDR3 aggravates the Tau pathology and cognitive impairment, and overexpression of ILDR3 significantly improves learning and memory function of a Tau pathology model and reduces nerve damage. Therefore, the ILDR3 gene and / or protein can be applied to preparation of a drug for preventing and / or treating a Tau-related disease and a diagnostic product.

Methods and systems for automatic classification, detection, assessment, and / or diagnosis of a pathology in a subject determine presence or absence, and / or a severity of various pathologies in a subject, for example, presence, absences, and / or severity of aortic stenosis in a heart of a subject.

To provide a drug for treating and preventing extracellular histone mediated ailments.SOLUTION: A drug comprises a polyanionic heptasulfated cellobioside modified with a small uncharged glycosidically linked substituent at its reducing terminus or a pharmaceutically acceptable salt thereof, the small uncharged glycosidically linked substituent being selected from the group consisting of O-(C1-6)alkyl and S-(C1-6)alkyl, and the extracellular histone mediated ailments being selected from the group consisting of systemic inflammatory response, trauma, burn, acute pancreatitis, acute kidney injury, acute respiratory distress syndrome, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, Crohn's disease, and rheumatoid arthritis.SELECTED DRAWING: None

Described herein are methods of making and using a transgenic mouse model of Alzheimer's disease. Transgenic animal models and cell lines are disclosed for the study of Alzheimer's disease or Alzheimer's disease-type pathology. Methods of screening and identifying active agents for the treatment of Alzheimer's disease or Alzheimer's disease-type pathology are also provided.

This application provides a method, electronic device, and medium for generating a disease diagnosis plan. The method includes: acquiring symptoms input by a user; obtaining macro nodes with semantically identical to the symptoms, and macro links where the macro nodes with semantically identical to the symptoms are located, based on the macro subnet; determining, based on the meso subnet, a meso node matching the macro node at the starting position of the macro link, and a meso link where the matching meso node is located, wherein the matching meso node represents the pathology of the symptoms; determining, based on the micro subnet, a micro node matching the meso node at the starting position of the meso link, and a micro link where the matching micro node is located, wherein the matching micro node represents the molecular information of the pathology; and determining a diagnosis plan based on the micro link, the meso link, and the macro link.

Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.

A phonocardiogram apparatus and related method for diagnosis of cardiac pathologies through advanced sound recording and analysis. This apparatus utilizes a grid of microphones embedded in a fabric and positioned over the patient's chest and back to capture heart, lung, and neck sounds from multiple locations. An artificial intelligence (AI) based algorithm is employed to determine the most relevant microphones based on the patient's unique anatomy, thereby optimizing sound collection for diagnostic purposes. The collected sounds undergo a series of pre-processing and machine learning analyses to diagnose cardiac abnormalities such as aortic stenosis, murmurs, and extra systoles, create cardiac auscultatory signatures and allow longitudinal monitoring by clinicians or patients themselves for comparison over time.

The invention discloses an A [beta]-PET image prediction method. The method belongs to the field of PET image generation, and mainly comprises the following steps: acquiring real A beta-PET images of an Alzheimer's disease patient at t0 and t1 moments, and clinical information meta such as a cognitive state of the patient at the t0 moment; in combination with spatial distribution characteristics of A [beta] deposition, the above data is used to train the neural network of the application. After training is completed, the real A beta-PET image at the current moment t0'and the clinical information meta 'of the patient are input into the neural network, and then the A beta-PET image in the future time interval can be predicted. According to the method, the early diagnosis rate of the Alzheimer's disease can be increased, long-term dynamic prediction of the intracerebral A beta pathology is achieved, and therefore the medical cost and the social burden are reduced.

The invention provides a Parkinson's disease auxiliary diagnosis kit based on an RT-QuIC technology and application of the Parkinson's disease auxiliary diagnosis kit, and belongs to the technical field of detection kits. The kit provided by the invention has remarkable minimally invasive property and high patient compliance, detection can be completed only by collecting trace skin tissues, and risks and pains of lumbar puncture or brain tissue biopsy are avoided. The kit has excellent detection performance, can realize highly sensitive and specific identification of early pathology of Parkinson's disease, has a fast detection process, can complete batch sample analysis in a short time, and powerfully supports clinical rapid diagnosis and screening requirements. Meanwhile, the overall cost is remarkably lower than that of existing methods such as imaging, a convenient, reliable and economical molecular detection means is provided for early discovery, clinical auxiliary diagnosis and treatment effect observation of the Parkinson's disease, and positive significance is achieved for improving the overall diagnosis and treatment level of the neurodegenerative diseases.

Disclosed are 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds for the treatment of various diseases and pathologies. More specifically, the present disclosure relates to the use of 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

The present invention relates to methods and compositions comprising a combination of oleuropein and / or metabolite thereof and adenosylcobalamin in an effective amount for use in achieving at least one result selected from the group consisting of i) preventing and / or treating a mitochondria-related disease or condition associated with altered mitochondrial function and / or ii) at least one physical state selected from the group consisting of oxidative stress or a condition associated with oxidative stress in an individual; (iii) increasing mitochondrial energy, cellular energy, mitochondrial function and mitochondrial calcium uptake in one or more cells, (iv) increasing resistance to age-related pathologies; (v) improving a physiological state or disorder related to cell ageing or metabolic fatigue in one or more cells; (vi) improving mobility and / or (vii) improving healthspan and / or lifespan in an individual.

This invention discloses a Raman spectroscopy-based detection technology for glioma IDH mutations, belonging to the field of tumor diagnosis. This invention prepares a core-shell structure based on gold nanoparticles and UiO-66, utilizing... N, N '-Di(2-aminoethyl)-1,3-propanediamine was used to modify the Raman signal of SERS-enhanced samples. Ratio analysis was then used to determine the presence of IDH mutations in gliomas, establishing a detection protocol for IDH mutations in glioma cells. This facilitates rapid intraoperative molecular pathology identification and provides effective guidance for surgical and subsequent treatment selection. The detection technology disclosed in this invention can obtain results within 2 minutes, greatly improving clinical diagnostic efficiency and enabling intraoperative molecular pathology diagnosis, which has significant clinical implications.

The present disclosure provides a compound of Formula I which are naphthalene monoimide compounds, and process of preparing thereof. The compounds of the present disclosure provide reversal of cognitive decline or improvement of cognitive decline. The compounds of Formula (I) of the present disclosure synergistically modulate metal independent and dependent amyloid toxicity, scavenge reactive oxidative species (ROS), alleviate oxidative stress, emulate Nrf2 mediated stress response, mitochondrial damage, microglial activation and neuroinflammation.